Frazier Life Sciences Management, L.P. Trevi Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,259,409 shares of TRVI stock, worth $62.8 Million. This represents 4.06% of its overall portfolio holdings.
Number of Shares
10,259,409
Previous 10,664,774
3.8%
Holding current value
$62.8 Million
Previous $45.4 Million
42.04%
% of portfolio
4.06%
Previous 2.72%
Shares
7 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$69.6 Million6.78% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$27.8 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$23.5 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.3 Million5.95% of portfolio
-
Bio Impact Capital LLC Cambridge, MA3.43MShares$21 Million3.99% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $357M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...